ProCE Banner Events

Share

2023 PCE Oncology Fall Conferences - Evening of Hematology

PCE, the national leader in continuing education for NPs and PAs, returns this November with our virtual Fall Oncology Conferences. These complimentary CE/CME meetings are tailored to meet the clinical needs and evolving scope of practice of NPs, PAs, and nurses who practice in oncology.
Register now and earn up to 3.0 CE/CME credits!

Pharmacists: 1.00 contact hour (0.1 CEUs)

US Physicians: maximum of 1.00 Medical Knowledge MOC point(s)

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Registered Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

Registered Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit 

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

This event has expired. No longer available for credits.

Who Should Attend

Oncology MDs, NPs, PharmDs, PAs, and RNs 

Time and location

Tuesday, November 14, 2023

5:00 PM - 10:00 PM Eastern Time (ET)

Virtual

Faculty
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Lindsey Lyle, MS, PA-C

Assistant Professor
Physician Assistant
Blood Disorders Center
University of Colorado
Aurora, Colorado

George Yaghmour, MD

Associate Director Transplant and Cellular Therapy Program
Blood and Marrow Transplant, Bone Marrow Transplant, Hematology
University of Southern California
Los Angeles, California

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Ajai Chari, MD

Director of Multiple Myeloma Program
Professor of Clinical Medicine
University of California- San Francisco
San Francisco, California

Agenda

Evening of Hematology (November 14, 2023)
Moderator:
Beth Faiman, PHD, CNP

5:00 PM – 5:55 PM: Recent Progress with CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice - Ajai Chari, MD

5:55 PM – 6:00 PM: Break

6:00 PM – 7:00 PM: Non-accredited Presentation Theater: Polycythemia Vera Clinical Case Discussion: When to Intervene With Jakafi® (ruxolitinib) - Sponsored by Incyte Corporation - Lindsey Lyle, MS, PA-C

7:00 PM – 7:55 PM: Current and Emerging Roles of BTK Inhibitors in CLL/SLL and MCL - Beth Faiman, PHD, CNP

7:55 PM – 8:00 PM: Break

8:00 PM – 9:00 PM: Non-accredited Presentation Theater: Understanding Ph+ALL, Treatment Goals, and Areas to Optimize - Sponsored by Takeda Oncology - George Yaghmour, MD

9:00 PM – 10:00 PM: Therapeutic Advances in Relapsed/Refractory DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy - John Burke, MD

CME/CE Info

Program Overview
This live webinar program is designed for nurse practitioners, physician associates, and nurses who practice in oncology and will provide accredited education covering timely, expert-led, evidence-based education across a range of different cancers to advance the care of patients with cancer.

Target Audience
Oncology MDs, NPs, PharmDs, PAs, and RNs 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the latest evidence in the treatment of cancer including recommended biomarker testing, safety and efficacy of available therapies, and strategies to address health disparities
  • Integrate evidence-based strategies into practice for managing and individualizing the care of patients with cancer
  • Assess toxicities associated with treatments for cancer and apply recommended management strategies

 

Accreditation

Joint Accreditation Statement


In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

     - Current and Emerging Roles of BTK Inhibitors in CLL/SLL and MCL: 1.0

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

     - Current and Emerging Roles of BTK Inhibitors in CLL/SLL and MCL: 1.0

IPCE Credit Designation

 

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

     - Current and Emerging Roles of BTK Inhibitors in CLL/SLL and MCL: 1.0


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

     - Recent Progress with CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice: 1.0

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

     - Recent Progress with CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice: 1.0

Continuing Pharmacy Education

A black and white logoDescription automatically generated

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-227-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

     - Recent Progress with CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice: 1.0

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) and Partners for Advancing Clinical Education (PACE) require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO and PACE policy. CCO and PACE are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     - Therapeutic Advances in Relapsed/Refractory DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy: 1.0

Nursing Continuing Professional Development

USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity. USF Health, the accredited provider, acknowledges Rockpointe as the joint provider in the planning and execution of this CNE activity.

This activity is awarded 1.0 ANCC pharmacotherapeutic contact hour.

     - Therapeutic Advances in Relapsed/Refractory DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy: 1.0

For information about accreditation of this activity, please email: cpdsupport@usf.edu 

ABIM MOC RECOGNITION STATEMENT


Successful completion of the CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is USF Health’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     - Therapeutic Advances in Relapsed/Refractory DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy: 1.0

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through USF Health’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Participants will earn MOC Points equivalent to the amount of CME credits claimed for the activity. USF Health will submit within 60 days the Participant’s MOC Points. No MOC certificates will be provided. Participants with questions regarding their Points, should contact USF Health at cpdsupport@usf.edu.

Relevant Financial Relationships Disclosures:
USF Health and Rockpointe adhere to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. Prior to the activity, USF Health will disclose and mitigate all relevant financial relationships that relate to the content of the activity.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) and Clinical Care Options, LLC

Recent Progress with CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice
Supported by an educational grant from Sanofi.

Current and Emerging Roles of BTK Inhibitors in CLL/SLL and MCL
Supported by an educational grant from Merck Sharp & Dohme LLC.

Therapeutic Advances in Relapsed/Refractory DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy
Supported by an educational grant from Regeneron Pharmaceuticals, Inc.